DLB

Dolby Laboratories Announces Conference Call and Webcast for Q4 Fiscal 2022 Financial Results

Retrieved on: 
Thursday, October 20, 2022
Atmos, SAN, Science, NYSE, Dolby Cinema, Music, Sport, Dolby Laboratories, DLB, GLOBE, Dolby Vision, Dolby Atmos, Communications satellite, Cassette tape

SAN FRANCISCO, Oct. 20, 2022 (GLOBE NEWSWIRE) -- Dolby Laboratories, Inc.(NYSE:DLB) will release financial results for the fourth quarter (Q4) of fiscal 2022 after the close of regular trading onThursday, November 17, 2022.

Key Points: 
  • SAN FRANCISCO, Oct. 20, 2022 (GLOBE NEWSWIRE) -- Dolby Laboratories, Inc.(NYSE:DLB) will release financial results for the fourth quarter (Q4) of fiscal 2022 after the close of regular trading onThursday, November 17, 2022.
  • Members ofDolbymanagement will lead a conference call open to all interested parties to discuss Q4 fiscal 2022 financial results forDolby Laboratoriesat2:00 p.m. PT(5:00 p.m.
  • An archived version of the teleconference will also be available on the Dolby Laboratories website, http://investor.dolby.com .
  • Dolby, Dolby Atmos, Dolby Vision, Dolby Cinema, Dolby.io, and the double-D symbol are among the registered and unregistered trademarks of Dolby Laboratories, Inc. in the United States and/or other countries.Other trademarks remain the property of their respective owners.

Cognition Therapeutics is Recruiting for Lewy Body Dementia Phase 2 SHIMMER Trial in Seventeen Research Sites Across the U.S.

Retrieved on: 
Wednesday, October 12, 2022
Lewy body, Therapy, Diagnosis, Degenerative disease, Delusion, Vance DeGeneres, Lewy, Hallucination, Private Securities Litigation Reform Act, Retina, Patient, Sleep, MPH, Mental health, NIA, Dementia, Nasdaq, Awareness, Risk, LBD, University, Neurology, Lewy Body Dementia Association, Neuron, U.S. Securities and Exchange Commission, National, Â, Securities & Exchange Commission of Pakistan, SHIMMER, Safety, Cognition, DLB, GLOBE, Neurodegeneration, Brain, Intellectual property, Practitioner, Pathology, Central nervous system, Biomarker, Pharmaceutical industry, Medicine, MD

The Phase 2 SHIMMER study ( NCT05225415 ) is actively recruiting participants for these sites across the United States, including those that are Lewy Body Dementia Association centers of excellence added Anthony O. Caggiano, M.D., Ph.D., Cognitions chief medical officer and head of R&D.

Key Points: 
  • The Phase 2 SHIMMER study ( NCT05225415 ) is actively recruiting participants for these sites across the United States, including those that are Lewy Body Dementia Association centers of excellence added Anthony O. Caggiano, M.D., Ph.D., Cognitions chief medical officer and head of R&D.
  • This month is Lewy Body Dementia Awareness month with approximately over 1.4 million people in the United States suffering from the neurodegenerative disease, making it the second most common form of dementia.
  • Often misdiagnosed it also masks itself as Parkinsons disease and is the largest dementia most have never heard of.
  • This October, during Lewy Body Dementia Awareness Month, lets recommit to educating ourselves about LBD.

Cognition Therapeutics Appoints CNS Drug Development Expert to VP Clinical Development

Retrieved on: 
Tuesday, October 11, 2022
Lewy body, Medical school, Pharmacology, Memorial Sloan Kettering Cancer Center, Cholinesterase, Therapy, University of California, San Diego, Degenerative disease, Pfizer, Private Securities Litigation Reform Act, Vance DeGeneres, Retina, Antibody, Fasinumab, Research, Dementia, Nasdaq, Anesthesiology, Risk, Nerve growth factor, U.S. Securities and Exchange Commission, Department, CEO, Pain, Securities & Exchange Commission of Pakistan, Cognition, Forest Laboratories, Chemistry, DLB, CNS, Temple University, GLOBE, Intellectual property, Chronic pain, Stony Brook University, Eisai, Central nervous system, Regeneron Pharmaceuticals, Bachelor of Science in Human Biology, Pharmaceutical industry, Science, Philosophy

Dr. Tiseo brings to Cognition more than two decades of strategic and operational expertise leading the clinical development of central nervous system (CNS) drug candidates, including Aricept and Namenda.

Key Points: 
  • Dr. Tiseo brings to Cognition more than two decades of strategic and operational expertise leading the clinical development of central nervous system (CNS) drug candidates, including Aricept and Namenda.
  • Dr. Tiseo was most recently the executive director of clinical development at Centrexion Therapeutics, a private biotechnology company focused on the development of non-opioid drugs for the treatment of acute and chronic pain.
  • At Centrexion he worked with the clinical operations and regulatory teams to develop and execute strategies for the clinical development of the companys lead Phase 3 candidate as well as a pipeline of earlier stage therapeutics.
  • Cognition Therapeutics, Inc. is a clinical-stage biopharmaceutical company engaged in the discovery and development of innovative, small molecule therapeutics targeting age-related degenerative disorders of the central nervous system and retina.

CND Life Sciences Awarded Third NIH SBIR Grant to Study the Syn-One Test® in Patients Diagnosed with REM Sleep Behavior Disorder (RBD)

Retrieved on: 
Thursday, October 6, 2022
Lewy body, National Institute, Movement, Risk, PD, REM, Diagnosis, Neurodegeneration, Patient, MSA, Behavioural sciences, Sleep, Government budget balance, National Institute of Neurological Disorders and Stroke, Parkinson's disease, Research, NIH, Lists of diseases, CND, National Institute on Aging, NIA, Dementia, Synucleinopathy, SBIR, Psychiatry, MD, Pure autonomic failure, NAPS, AI, RBD, National, Neurology, PAF, Multiple system atrophy, DLB, Alpha-synuclein, Gold, Stanford University, Dysautonomia, Radical behaviorism, Stroke, Rapid eye movement sleep behavior disorder, Movement disorders, Pathology, Pharmaceutical industry, Medical imaging

PHOENIX, Oct. 6, 2022 /PRNewswire/ -- CND Life Sciences, an innovative medical diagnostics company pioneering the detection, visualization, and quantification of protein deposition in cutaneous nerve fibers, has been awarded a $3 million Phase II Small Business Innovation Research (SBIR) grant from the National Institute on Aging (NIA) of the National Institutes of Health (NIH). This is the third NIH SBIR Phase II award for the company to study and advance the clinical application of the Syn-One Test, the only commercially available test that uses skin biopsies to help clinicians diagnose a synucleinopathy, a family of neurodegenerative diseases that includes Parkinson's disease (PD), dementia with Lewy bodies (DLB), and multiple system atrophy (MSA), pure autonomic failure (PAF) and REM sleep behavior disorder (RBD).

Key Points: 
  • Patients diagnosed with RBD experience vivid, often disruptive dreams associated with simple or complex motor behavior during the REM phase of sleep.
  • The success of future treatments for these disorders will be tied to how precisely and early we can understand the patient's pathology," explained Levine.
  • Founded in 2017, CND Life Sciences is dedicated to supporting the care of patients facing the potential diagnosis of a neurodegenerative disease and other neurological conditions.
  • The company has research collaborations with multiple biopharmaceutical companies and has been awarded three prestigious NIH SBIR grants to advance the validation and clinical utility of its Syn-One Test.

Cognition Therapeutics to Participate in the 2022 Cantor Fitzgerald Neurology & Psychiatry Conference

Retrieved on: 
Thursday, September 29, 2022
U.S. Securities and Exchange Commission, Therapy, Central nervous system, Retina, Degenerative disease, Securities & Exchange Commission of Pakistan, Lewy body, COVID-19, Intellectual property, Cognition, DLB, Risk, CEO, Vance DeGeneres, Cantor, Nasdaq, Private Securities Litigation Reform Act, Dementia, Conference, GLOBE, Pharmaceutical industry, Risk management

Details of Cognitions participation in the conference are as follows:

Key Points: 
  • Details of Cognitions participation in the conference are as follows:
    The panel presentation will be available only to conference participants and no webcast will be available.
  • To schedule a meeting with Cognitions management team during the conference, please contact your Cantor representative.
  • Cognition Therapeutics, Inc. is a clinical-stage biopharmaceutical company engaged in the discovery and development of innovative, small molecule therapeutics targeting age-related degenerative disorders of the central nervous system and retina.
  • We believe CT1812 and our pipeline of -2 receptor modulators can regulate pathways that are impaired in these diseases.

Cognition Therapeutics Awarded $2.14 Million in Supplemental Grant Funding from NIA to Support SEQUEL Clinical Trial

Retrieved on: 
Tuesday, September 27, 2022
Theta, Institute, National, Therapy, Central nervous system, Retina, SEQUEL, U.S. Securities and Exchange Commission, Safety, Degenerative disease, Securities & Exchange Commission of Pakistan, Lewy body, COVID-19, Brain, Amsterdam, Intellectual property, National Institute on Aging, MMSE, Cognition, DLB, Patient, NIA, Risk, CEO, Jort, Vance DeGeneres, Nasdaq, Private Securities Litigation Reform Act, Dementia, Research, EEG, GLOBE, Quantitative electroencephalography, NIH, National Institute, Pharmaceutical industry

The aim of the SEQUEL trial is to investigate whether treatment with CT1812 results in a normalization of the EEG patterns, as measured by quantitative electroencephalogram (qEEG).

Key Points: 
  • The aim of the SEQUEL trial is to investigate whether treatment with CT1812 results in a normalization of the EEG patterns, as measured by quantitative electroencephalogram (qEEG).
  • We also want to extend our gratitude to the patients who enrolled in SEQUEL and the team at Amsterdam UMC who remained engaged through the pandemic.
  • After a 14-day wash-out period, participants cross over into the other treatment arm for an additional 28 days (period 2).
  • The NIA awarded Cognition a $3.2 million grant (R01AG058710) in 2020 to support the study and has now subsequently awarded $2.14 million in 2022.

EIP Pharma Publishes Translational Data of Preclinical and Phase 2a Results for Neflamapimod in Dementia with Lewy Bodies: Nature Communications

Retrieved on: 
Wednesday, September 21, 2022
Professional Services, Health, Clinical Trials, Banking, Pharmaceutical, Biotechnology, Acetylcholine, Therapy, Neurodegeneration, Lists of diseases, Lewy body, Average absolute deviation, MAP, Ageing, FDA, MD, Food, Basal forebrain, Research, Brain, Government budget balance, Even and odd functions, Company, EIP, Nathan, Cognition, DLB, Patient, Neurological disorder, Attention, Timed Up and Go test, Center, TUG, Doctor of Philosophy, Nature Communications, Body, Drug development, CNS, NTB, Neuron, Lewy, Disease, Pharmaceutical industry, Dementia

The animal studies in the publication show that neflamapimod reduces Rab5 activity and reverses the neurodegenerative process in the basal forebrain.

Key Points: 
  • The animal studies in the publication show that neflamapimod reduces Rab5 activity and reverses the neurodegenerative process in the basal forebrain.
  • These combined pre-clinical and clinical results provide a foundation for a confirmatory, hypothesis-testing Phase 2b clinical study evaluating neflamapimod for DLB.
  • The data published today provide us confidence to progress neflamapimod into a confirmatory Phase 2b clinical trial in Dementia with Lewy Bodies.
  • et al., Preclinical and Randomized Clinical Evaluation of the p38 Kinase Inhibitor Neflamapimod for Basal Forebrain Cholinergic Degeneration, Nature Communications, 13, Article number: 5308 (2022).

Winners of the Dolby Institute x Ghetto Film School Filmmaker Challenge: Finish the Script Year 2 Announced

Retrieved on: 
Monday, September 19, 2022
Atmos, Dolby Atmos, Raya, Culture, Dolby Laboratories, NYSE, GFS, Organization, Academy Awards, Partnership, DLB, Film, EMERGE, Program, Technology, Dolby Vision, SAN, GLOBE, Script

SAN FRANCISCO, Sept. 19, 2022 (GLOBE NEWSWIRE) -- Dolby Laboratories, Inc. (NYSE:DLB), a leader in immersive entertainment experiences, and award-winning nonprofit Ghetto Film School (GFS), today announced the winners of the Dolby Institute x Ghetto Film School Filmmaker Challenge: Finish the Script Year 2.

Key Points: 
  • SAN FRANCISCO, Sept. 19, 2022 (GLOBE NEWSWIRE) -- Dolby Laboratories, Inc. (NYSE:DLB), a leader in immersive entertainment experiences, and award-winning nonprofit Ghetto Film School (GFS), today announced the winners of the Dolby Institute x Ghetto Film School Filmmaker Challenge: Finish the Script Year 2.
  • In addition, a Dolby team will be available to provide inspiration and guidance to the winners on how to best use the ultravivid color of Dolby Vision and the immersive sound of Dolby Atmos to complete their projects.
  • The Finish the Script challenge is designed to support early career filmmakers by placing them in positions of creative leadership, said Ghetto Film School CEO and alumna, Montea Robinson.
  • For more information about the Dolby Institute x Ghetto Film School Filmmaker Challenge: Finish the Script Year 2 and to watch films from last years winners, please visit

Cognition Therapeutics Announces Participation in September Investment Conferences

Retrieved on: 
Tuesday, September 6, 2022
Vance DeGeneres, Security (finance), Central nervous system, Therapy, Degenerative disease, Lewy body, Retina, Risk, Private Securities Litigation Reform Act, Cognition, DLB, U.S. Securities and Exchange Commission, GLOBE, Nasdaq, Dementia, Investor, Pharmaceutical industry

PURCHASE, N.Y., Sept. 06, 2022 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (Nasdaq: CGTX) (the Company or Cognition), a clinical-stage biopharmaceutical company engaged in the discovery and development of innovative, small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina, today announced that members of management will be participating in two investment conferences in September 2022.

Key Points: 
  • PURCHASE, N.Y., Sept. 06, 2022 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (Nasdaq: CGTX) (the Company or Cognition), a clinical-stage biopharmaceutical company engaged in the discovery and development of innovative, small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina, today announced that members of management will be participating in two investment conferences in September 2022.
  • In addition, the Cognition management team will be available for one-on-one meetings during the conferences.
  • Cognition Therapeutics, Inc. is a clinical-stage biopharmaceutical company engaged in the discovery and development of innovative, small molecule therapeutics targeting age-related degenerative disorders of the central nervous system and retina.
  • More about Cognition Therapeutics and its pipeline can be found at https://cogrx.com .

AC Immune Receives a Grant from The Michael J. Fox Foundation for Continued Development of Parkinson’s Disease Diagnostic Imaging Agent

Retrieved on: 
Thursday, September 1, 2022
PSP, PET, NLRP3, CEO, Janssen Pharmaceuticals, Spinocerebellar ataxia, Program, NOD, NIH Intramural Research Program, MJFF, Alpha-synuclein, AC, NASDAQ, Brain, Doctor of Philosophy, Time, Disease, Precision medicine, USD, Hoffmann-La Roche, Genentech, Diagnosis, The Michael J. Fox Foundation, DLB, Senior, MSA, GMP, GLOBE, PD, Company, Neurodegeneration, SCA, AD, Eli Lilly and Company, Patient, Multiple system atrophy, Medical imaging, Pharmaceutical industry

Fox Foundation for Parkinsons Research (MJFF) awarded the Company a new grant to continue development of its Morphomer-based alpha-synuclein (a-syn) positron emission tomography (PET) tracer, ACI-12589.

Key Points: 
  • Fox Foundation for Parkinsons Research (MJFF) awarded the Company a new grant to continue development of its Morphomer-based alpha-synuclein (a-syn) positron emission tomography (PET) tracer, ACI-12589.
  • AC Immunehas received continuous grant support from MJFF since 2015 to develop a-syn PET tracers.
  • If successful, AC Immunes a-syn PET tracer program could deliver the worlds first imaging agent capable of accurately detecting and monitoring progression of Parkinsons disease (PD).
  • ACI-12589 also displayed pharmacokinetic and safety profiles suitable for further development as a human brain PET imaging agent.